Topics

OncoResponse Company Profile

14:03 EDT 21st September 2019 | BioPortfolio

OncoResponse discovers and develops highly targeted and immuno-oncology therapeutic antibodies against novel cancer targets. Our most advanced program, ONCR-201 is an anti-EMP2 fully-human monoclonal antibody being developed for female malignancies. The OncoResponse discovery engine is working to increase the success rate of cancer immunotherapies by identifying novel antibody drug candidates across multiple cancer types from the immune systems of patients who have responded exceptionally well to cancer immunotherapies. www.oncoresponseinc.com


News Articles [1 Associated News Articles listed on BioPortfolio]

OncoResponse’s Anil Singhal Named Adicet Bio President & CEO

Anil Singhal has been appointed president and CEO of Adicet Bio. He succeeds Donald Santel, who had been interim CEO since founder and former CEO Aya Jakobovits retired last year. Santel will continue...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

OncoResponse

OncoResponse discovers and develops highly targeted and immuno-oncology therapeutic antibodies against novel cancer targets. Our most advanced program, ONCR-201 is an anti-EMP2 fu...

More Information about "OncoResponse" on BioPortfolio

We have published hundreds of OncoResponse news stories on BioPortfolio along with dozens of OncoResponse Clinical Trials and PubMed Articles about OncoResponse for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of OncoResponse Companies in our database. You can also find out about relevant OncoResponse Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record